ChemMedChem最新文献_第3页

Nicorandil repurposing in orofacial pain: preclinical findings in adult zebrafish. 尼可地尔在口面部疼痛中的再利用：成年斑马鱼的临床前研究结果。

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-03-22 DOI: 10.1002/cmdc.202401007

José Ismael de Araújo, Gerlânia Leite, Leonardo da Silva-Neto, Antonio Eufrásio Vieira-Neto, Angelo de Fátima, Adriana Rolim Campos

{"title":"Nicorandil repurposing in orofacial pain: preclinical findings in adult zebrafish.","authors":"José Ismael de Araújo, Gerlânia Leite, Leonardo da Silva-Neto, Antonio Eufrásio Vieira-Neto, Angelo de Fátima, Adriana Rolim Campos","doi":"10.1002/cmdc.202401007","DOIUrl":"https://doi.org/10.1002/cmdc.202401007","url":null,"abstract":"This study investigated the orofacial antinociceptive activity of nicorandil in adult zebrafish and explored the involvement of TRP channels in this effect. Nicorandil, a known antianginal drug, reduced nociceptive behaviors induced by capsaicin (TRPV1 agonist), cinnamaldehyde (TRPA1 agonist), and menthol (TRPM8 agonist) without altering the locomotor activity of the zebrafish. Pre-treatment with specific TRPA1 and TRPV1 antagonists prevented the antinociceptive effects of nicorandil, indicating its action on these channels. Molecular docking studies supported these findings, demonstrating high chemical affinity and specific binding of nicorandil to the TRPV1 and TRPA1 channels, leading to stabilization and reduced biological activity of these channels. In contrast, the antinociceptive effect of nicorandil on menthol-induced nociception was not affected by a TRPM8 antagonist, suggesting that TRPM8 modulation is not involved in nicorandil's mechanism of action. The study highlights the potential of nicorandil as an analgesic through its interaction with TRPV1 and TRPA1 channels, providing a molecular basis for repositioning nicorandil as an effective analgesic drug.","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202401007"},"PeriodicalIF":3.6,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Two Targets, One Mission: Heterobivalent Metal-Based Radiopharmaceuticals for Prostate Cancer Imaging and Therapy. 两个目标，一个任务：前列腺癌成像和治疗的异双价金属基放射性药物。

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-03-21 DOI: 10.1002/cmdc.202500128

Margarida C Sobral, Sandra I Mota, Paulo J Oliveira, Ana M Urbano, António Paulo

{"title":"Two Targets, One Mission: Heterobivalent Metal-Based Radiopharmaceuticals for Prostate Cancer Imaging and Therapy.","authors":"Margarida C Sobral, Sandra I Mota, Paulo J Oliveira, Ana M Urbano, António Paulo","doi":"10.1002/cmdc.202500128","DOIUrl":"10.1002/cmdc.202500128","url":null,"abstract":"Prostate cancer (PCa) is a significant healthcare challenge, associated with considerable mortality and morbidity among men, particularly in developed countries. PCa mortality and morbidity are primarily related to its most advanced form, metastatic castration-resistant PCa (mCRPC), for which there is presently no cure. Therefore, novel therapeutic approaches to increase mCRPC survival are critically needed. Due to PCa tumor heterogeneity and a complex tumor microenvironment, the efficacy of single-target radiopharmaceuticals, such as the Food and Drug Administration-approved [177Lu]Lu-PSMA-617, is currently under reassessment. The design and development of PCa dual-target radiopharmaceuticals have garnered considerable attention, due to their benefits over single-target counterparts, namely increased therapeutic specificity and efficacy, as well as the ability to overcome the challenge of inconsistent tumor visualization caused by variable receptor expression across diverse lesions, thereby enabling more comprehensive imaging. Several PCa biomarkers are currently being investigated as potential targets for dual-target radiopharmaceuticals, including prostate-specific membrane antigen, gastrin-releasing peptide receptor, integrin αvβ3 receptor, fibroblast activation protein, sigma-1 receptor, as well as albumin, the radiosensitive cell nucleus, and mitochondria. This review explores recent advancements in heterobivalent metal-based radiopharmaceuticals for dual targeting in PCa, highlighting their significance in theranostic and personalized medicine.","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e2500128"},"PeriodicalIF":3.6,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143672999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Small-Molecule KRAS Inhibitors by Tyrosine Covalent Bond Formation. 酪氨酸共价键形成的小分子KRAS抑制剂。

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-03-18 DOI: 10.1002/cmdc.202400624

Alexander Landgraf, Robert Brenner, Mona Ghozayel, Khuchtumur Bum-Erdene, Giovanni Gonzalez-Gutierrez, Samy Meroueh

{"title":"Small-Molecule KRAS Inhibitors by Tyrosine Covalent Bond Formation.","authors":"Alexander Landgraf, Robert Brenner, Mona Ghozayel, Khuchtumur Bum-Erdene, Giovanni Gonzalez-Gutierrez, Samy Meroueh","doi":"10.1002/cmdc.202400624","DOIUrl":"https://doi.org/10.1002/cmdc.202400624","url":null,"abstract":"The development of the KRAS G12C inhibitor sotorasib was a major advance towards drugging KRAS. However, the G12C mutation is only found in about 10% of tumors with a KRAS mutation. KRAS tyrosine amino acids could provide alternative sites for covalent drug development. Here, we screen a library of aryl sulfonyl fluorides to explore whether tyrosines on KRAS are accessible for covalent bond formation. We identify compound 1 (SOF-436), which inhibits KRAS nucleotide exchange by guanine exchange factor SOS1 and the binding of KRAS to effector protein RAF. Tyr-64 was the major reaction site of 1 (SOF-436), although minor reaction at Tyr-71 was also observed. The fragment engages the Switch II pocket of KRAS based on mass spectrometry, nucleotide exchange, effector protein binding, nuclear magnetic resonance (NMR), and molecular dynamics simulations. Co-crystal structures of smaller fragments covalently bound to KRAS at Tyr-71 provide a strategy for the development of Switch I/II KRAS covalent inhibitors. A NanoBRET assay revealed that the compound and its analogs inhibit KRAS binding to RAF in mammalian cells. Although not yet suitable as chemical probes, these fragments provide starting points for small molecules to investigate tyrosine as a nucleophile for covalent inhibition of KRAS in tumors.","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202400624"},"PeriodicalIF":3.6,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143655788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Novel Inhibitor against the Bromodomain Protein 1 of the Malaria Pathogen Plasmodium Falciparum. 一种抗疟疾病原体恶性疟原虫溴结构域蛋白1的新型抑制剂。

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-03-18 DOI: 10.1002/cmdc.202500024

Marius Amann, Robin Warstat, Kay Kristin Rechten, Philip Theuer, Magdalena Schustereder, Sophie Clavey, Bernhard Breit, Oliver Einsle, Martin Hügle, Michaela Petter, Stefan Günther

{"title":"A Novel Inhibitor against the Bromodomain Protein 1 of the Malaria Pathogen Plasmodium Falciparum.","authors":"Marius Amann, Robin Warstat, Kay Kristin Rechten, Philip Theuer, Magdalena Schustereder, Sophie Clavey, Bernhard Breit, Oliver Einsle, Martin Hügle, Michaela Petter, Stefan Günther","doi":"10.1002/cmdc.202500024","DOIUrl":"10.1002/cmdc.202500024","url":null,"abstract":"The rise of drug resistances in malaria necessitates the exploration of novel therapeutic strategies. Targeting epigenetic pathways could open new, promising treatment avenues. In this study, the focus is on the essential Bromodomain protein 1 (PfBDP1) of the malaria pathogen Plasmodium falciparum. Utilizing the pan-selective bromodomain inhibitor MPM6, a potent initial hit is identified and it is subsequently developed into a nanomolar binder. Through a combination of virtual docking, isothermal titration calorimetry, and X-ray crystallography, the molecular interactions of the new inhibitors with the bromodomain (BRD) of the protein (PfBDP1-BRD) are elucidated. The findings include the first co-crystallized inhibitors with the structures of PfBRD1-BRD as well as the bromodomain of the close homologous protein of Plasmodium vivax (PvBDP1-BRD). The structures provide new insights into their binding mechanisms. Further validation using conditional knockdown of PfBDP1 in P. falciparum demonstrates parasite sensitivity to the inhibitor, underscoring its potential in a targeted therapeutic approach against malaria.","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e2500024"},"PeriodicalIF":3.6,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143655641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Diclofenac Derivatives: Exploring Carborane-Substituted N-Methyl and Nitrile Analogs for Anti-Cancer Therapy. 双氯芬酸衍生物的研究进展：碳硼烷取代n -甲基和腈类似物抗癌治疗的探索。

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-03-18 DOI: 10.1002/cmdc.202500084

Christoph Selg, Robert Schuster, Aleksandr Kazimir, Peter Lönnecke, Mara Wolniewicz, Jonas Schädlich, Markus Laube, Jens Pietzsch, Vuk Gordić, Tamara Krajnović, Sanja Mijatović, Danijela Maksimović-Ivanić, Evamarie Hey-Hawkins

{"title":"Advances in Diclofenac Derivatives: Exploring Carborane-Substituted N-Methyl and Nitrile Analogs for Anti-Cancer Therapy.","authors":"Christoph Selg, Robert Schuster, Aleksandr Kazimir, Peter Lönnecke, Mara Wolniewicz, Jonas Schädlich, Markus Laube, Jens Pietzsch, Vuk Gordić, Tamara Krajnović, Sanja Mijatović, Danijela Maksimović-Ivanić, Evamarie Hey-Hawkins","doi":"10.1002/cmdc.202500084","DOIUrl":"https://doi.org/10.1002/cmdc.202500084","url":null,"abstract":"This study explores the anti-cancer potential of N-methylated open-ring derivatives of carborane-substituted diclofenac analogs. By N-methylation, the open-chain form could be trapped and cyclization back to lactam or amidine derivatives was inhibited. A small library of carborane- and phenyl-based secondary and tertiary arylamines bearing carboxylic acid or nitrile groups was synthesized and analyzed for their COX-affinity in vitro and in silico. The compounds were further evaluated against mouse adenocarcinoma (MC38), human colorectal carcinoma (HCT116) and human colorectal adenocarcinoma (HT29) cell lines and showed potent cytotoxicity. Additional biological assessments of the mode of action were performed using flow cytometric techniques and fluorescence microscopy. The data obtained revealed a common antiproliferative effect coupled with the induction of caspase-independent apoptosis and the specific effects of the compound on the phenotype of MC38 cells, resulting in impaired cell viability of MC38 cells and satisfactory selectivity exceeding the antitumor activity of diclofenac.","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500084"},"PeriodicalIF":3.6,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143655770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Front Cover: Beyond the Toll-Like Receptor 4. Structure-Dependent Lipopolysaccharide Recognition Systems: How far are we? (ChemMedChem 6/2025) 封面：超越 Toll-Like 受体 4。结构依赖性脂多糖识别系统：我们还有多远？(ChemMedChem 6/2025)

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-03-16 DOI: 10.1002/cmdc.202580601

Stefania De Chiara, Luca De Simone Carone, Roberta Cirella, Dr. Emanuela Andretta, Prof. Alba Silipo, Prof. Antonio Molinaro, Dr. Marcello Mercogliano, Prof. Flaviana Di Lorenzo

{"title":"Front Cover: Beyond the Toll-Like Receptor 4. Structure-Dependent Lipopolysaccharide Recognition Systems: How far are we? (ChemMedChem 6/2025)","authors":"Stefania De Chiara, Luca De Simone Carone, Roberta Cirella, Dr. Emanuela Andretta, Prof. Alba Silipo, Prof. Antonio Molinaro, Dr. Marcello Mercogliano, Prof. Flaviana Di Lorenzo","doi":"10.1002/cmdc.202580601","DOIUrl":"https://doi.org/10.1002/cmdc.202580601","url":null,"abstract":"Gram-negative bacteria release lipopolysaccharides (LPS) into our bodies, acting as potent modulators of inflammation. These molecules can enhance or attenuate inflammation. Beyond the largely studied MD2/TLR4, a complex set of other receptors interact with LPS producing diverse effects. Understanding how the structural features of LPS affect the activity and crosstalk among various receptors is crucial for developing new drugs to treat immune-related pathologies. This review aims to persuade researchers with interest in this field to perform their research activities by always using a structure to function approach. More details can be found in article cmdc.202400780 by Marcello Mercogliano, Flaviana Di Lorenzo, and co-workers. \u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture>\u0000 </div>\u0000 </figure>\u0000 ","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"20 6","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202580601","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cover Feature: Improving Affinity while Reducing Kidney Uptake of CXCR4-Targeting Radioligands Derived from the Endogenous Antagonist EPI-X4 (ChemMedChem 6/2025) 封面特征：内源性拮抗剂EPI-X4衍生的靶向cxcr4的放射配体在提高亲和力的同时减少肾脏摄取（ChemMedChem 6/2025）

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-03-16 DOI: 10.1002/cmdc.202580604

Dr. Raghuvir H. Gaonkar, Dr. Thibaud Bailly, Dr. Jacopo Millul, Dr. Rosalba Mansi, Dr. Mirja Harms, Prof. Dr. Jan Münch, Prof. Dr. Melpomeni Fani

引用次数: 0

Enhancing WRAP-based Nanoparticles for siRNA Delivery in pH-Sensitive Environments. 在ph敏感环境中增强基于wrap的siRNA递送纳米颗粒。

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-03-14 DOI: 10.1002/cmdc.202400885

Giulia Di Gregorio, Coélio Vallée, Karidia Konate, Clémentine Teko-Agbo, Thania Hammoum, Héloïse Faure-Gautron, Yannick Bessin, Sebastien Deshayes, Eric Vivès, Albano C Meli, Pascal de Santa Barbara, Sandrine Faure, Stéphanie Barrère-Lemaire, Sebastien Ulrich, Prisca Boisguérin

{"title":"Enhancing WRAP-based Nanoparticles for siRNA Delivery in pH-Sensitive Environments.","authors":"Giulia Di Gregorio, Coélio Vallée, Karidia Konate, Clémentine Teko-Agbo, Thania Hammoum, Héloïse Faure-Gautron, Yannick Bessin, Sebastien Deshayes, Eric Vivès, Albano C Meli, Pascal de Santa Barbara, Sandrine Faure, Stéphanie Barrère-Lemaire, Sebastien Ulrich, Prisca Boisguérin","doi":"10.1002/cmdc.202400885","DOIUrl":"https://doi.org/10.1002/cmdc.202400885","url":null,"abstract":"SiRNA are promising therapeutic molecules that require delivery systems to reach their targets. Several siRNA delivery systems, such as lipid- or peptide-based nanoparticles, have been developed. In this context, we previously conceived a cell-penetrating peptide WRAP5 forming nanoparticles in the presence of siRNAs and validated the efficiency of this delivery system in inhibiting protein expression. In the pathophysiological context of acute myocardial infarction, which causes a pH drop in the ischemic heart tissue, we optimized the WRAP5-based nanoparticles for a pH-sensitive siRNA-targeted delivery. Therefore, pH-sensitive acyl hydrazone linkers were used to graft polyethylene (PEG) on the WRAP5 peptide. Proof of concept of the targeted delivery was performed using siRNA silencing the Fas-associated death domain (FADD) containing protein implicated in apoptosis during myocardial ischemia-reperfusion injury on two human cell models (vascular endothelial cells and hiPSC-derived cardiomyocytes). Our results show that only WRAP5 nanoparticles PEGylated via an appropriate acyl hydrazone linker with tuned pH sensitivity can induce a specific FADD knockdown at pH 5 compared to naked nanoparticles. These optimized WRAP-based nanoparticles could be a novel therapeutic tool for treating myocardial infarction by inhibiting apoptosis induced by reperfusion and maximizing local delivery of the nanoparticle content at the site of injured cells.","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202400885"},"PeriodicalIF":3.6,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrin Ring Modification in Peptide Drug Development - a Brief History of "Corrination". 肽药物开发中的科林斯环偶联-“科林斯”简史。

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-03-13 DOI: 10.1002/cmdc.202500129

Nancy Cham, Robert P Doyle

{"title":"Corrin Ring Modification in Peptide Drug Development - a Brief History of \"Corrination\".","authors":"Nancy Cham, Robert P Doyle","doi":"10.1002/cmdc.202500129","DOIUrl":"10.1002/cmdc.202500129","url":null,"abstract":"Recently, the term \"corrination\" was coined to describe the conjugate modification of a peptide, protein, small molecule, or radionuclide with a corrin ring-containing molecule. By exploiting the innate chemicophysical properties of corrin ring-containing compounds, corrination has been explored for drug development and targeted/localized delivery of probes and therapeutics. Most recently, it is in the field of peptide-based therapeutics that corrination is generating significant interest. Peptide-based drugs possess several limitations that restrict their clinical application, including poor solubility and stability, low oral bioavailability, and negative side effects often due to drug distribution. In this mini review, the design and synthetic approaches to peptide corrination are described, along with examples of in vitro, ex vivo, and in vivo biological evaluations of corrinated conjugates, which demonstrate the broad applicability of the technique, namely 1) mitigated peptide aggregation, 2) improved protection against proteolysis, 3) reduced negative side effects via targeted localization, 4) regioselective production of peptide disulfide bonds, and 5) improved oral drug absorption. Herein, it is described how corrination offers a facile route to improving peptide pharmacokinetic and pharmacodynamic properties, making this a useful platform technology in the field of peptide drug development.","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e2500129"},"PeriodicalIF":3.6,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Significant Tumor Inhibition of Trimethyl-152-[L-aspartyl]pheophorbide a in Tumor Photodynamic Therapy‡. 三甲基-152-[l-天冬氨酸]酚a在肿瘤光动力治疗中的显著肿瘤抑制作用

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-03-12 DOI: 10.1002/cmdc.202500087

Davor Margetic, Anita Benić, Akmaral Kussayeva, Ivana Antol, Mario Vazdar, Zlatko Brkljača, Dan-Ye Chen, Yi-Jia Yan, Ying-Hua Gao, Zhi-Long Chen

引用次数: 0